arGEN-x N.V. Announces Changes to the Board of Directors
News Apr 14, 2015
arGEN-X N.V. has announced the resignation of non-executive directors Bruno Montanari and Harrold van Barlingen from the Board of Directors per 13 May 2015.
Mr. Van Barlingen has been involved with arGEN-X B.V. since 2008, Mr. Montanari joined as a supervisory director of arGEN-X B.V. in 2012. In line with the requirements of the Dutch Corporate Governance Code, both directors will be replaced by independent industry professionals.
As announced on 1 April, Mr. D. deBethizy shall be recommended for appointment as non-executive director to the board during the annual meeting of shareholders of 13 May 2015. Furthermore, arGEN-X announces that Mrs. P. Klein has agreed to serve as an advisor to the board of directors as from 13 May 2015. Mrs. Klein is an experienced biotech and pharma executive with successful stints at Genentech as Vice President Oncology and at Intellikine as Chief Medical Officer.
The board of arGEN-X intends to recommend Mrs. Klein for appointment as non-executive director to the board at the next shareholders' meeting following the annual meeting of 13 May 2015.
“I have great confidence that the new Board will be instrumental in taking arGEN-X to the next level and continuing to build significant value for our shareholders. I would also like to take this opportunity to thank Bruno and Harrold for their very important contributions as Directors over the past years,” commented Peter Verhaeghe, Chairman of the Board of Directors.
Malaria Prevention: New Antibody Targets Unique Binding SiteNews
Scientists have discovered a human antibody that, when tested in mice, prevented malaria infection by binding a specific portion of a surface protein found in almost all strains of the malaria parasite worldwide.READ MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Combination Drug Trial Launched to Eradicate B-Cell MalignanciesNews
Researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined effectiveness of a standard of care drug with a novel monoclonal antibody that target B-cell malignancies, which include leukemias and lymphomas.READ MORE